What is the recommended treatment for acute heart failure according to standard guidelines?

Acute Heart Failure Treatment According to Standard Guidelines

Intravenous loop diuretics are the cornerstone of acute heart failure (AHF) treatment and should be administered within 60 minutes of presentation in patients with signs of congestion, with an initial dose of 20-40 mg furosemide IV (or equivalent) in diuretic-naïve patients or double the home oral dose in those already on diuretics 1.

Initial Assessment and Monitoring

Upon presentation, immediately obtain:

• ECG and transthoracic echocardiography (TTE) to assess cardiac structure, function, and LVEF 1
• Vital signs with continuous monitoring of blood pressure and oxygen saturation
• Clinical phenotyping based on congestion (wet vs. dry) and perfusion (warm vs. cold)

The clinical profile guides treatment selection. Most AHF patients present with congestion ("wet") requiring decongestion strategies 1.

Pharmacological Management Algorithm

1. Diuretic Therapy (Class I, Level B)

Initial dosing strategy 1:

• Diuretic-naïve: 20-40 mg IV furosemide
• Already on diuretics: Double the oral home dose IV
• Administer as intermittent boluses or continuous infusion (both equally effective)

Monitoring response within first 6 hours 2:

• Target urine output: ≥100-150 mL/hour after 6 hours
• Spot urinary sodium: ≥50-70 mmol/L after 2 hours
• If targets not met, double the dose (maximum 400-600 mg/day, up to 1000 mg/day in severe renal dysfunction)

For diuretic resistance 1:

• Combination therapy with thiazide-type diuretic or spironolactone (Class IIb, Level C)
• Consider acetazolamide 500 mg IV once daily for first 3 days, particularly if baseline bicarbonate ≥27 mmol/L 2

Critical monitoring: Regularly assess symptoms, urine output, renal function, and electrolytes 1.

2. Vasodilators (Class IIa, Level B)

IV vasodilators should be considered in patients with:

• SBP >90 mmHg without symptomatic hypotension 1
• Hypertensive AHF as initial therapy to improve symptoms and reduce congestion 1

Monitor blood pressure frequently during administration. Vasodilators provide symptomatic relief through afterload reduction and venodilation 1.

3. Respiratory Support

Non-invasive positive pressure ventilation (CPAP or bi-level PPV) reduces respiratory distress and may decrease intubation rates 1. Use:

• CPAP in pre-hospital and early hospital settings
• PS-PEEP if acidosis, hypercapnia, or COPD history present
• Oxygen supplementation targeting appropriate SpO₂ (avoid hyperoxia)

4. Inotropic Agents - Use With Extreme Caution

Inotropes are NOT recommended unless the patient has symptomatic hypotension (SBP <90 mmHg) or hypoperfusion (Class III, Level A) 1. This is a critical safety concern as inotropes increase mortality risk 1.

If hypotension/hypoperfusion present (Class IIb, Level C):

• Short-term IV dobutamine, levosimendan, or PDE III inhibitors may be considered
• Levosimendan preferred over dobutamine to reverse beta-blockade effects
• Continuous ECG and blood pressure monitoring mandatory due to arrhythmia and ischemia risk 1

5. Vasopressors

Norepinephrine (preferred vasopressor) may be considered in cardiogenic shock despite inotrope treatment (Class IIb, Level B) 1.

Cardiogenic Shock Management

For patients with SBP <90 mmHg despite adequate filling with signs of hypoperfusion 3:

1. Immediate ECG and echocardiography (Class I, Level C)
2. Transfer to tertiary center with 24/7 cardiac catheterization and ICU/CCU capabilities (Class I, Level C)
3. Immediate coronary angiography within 2 hours if ACS-related (Class I, Level C) 3
4. Invasive arterial line monitoring (Class I, Level C)
5. Inotrope (dobutamine) + vasopressor (norepinephrine) as needed
6. Consider mechanical circulatory support if inadequate response

Important caveat: IABP is NOT routinely recommended in cardiogenic shock (no mortality benefit demonstrated) 3.

Additional Therapies

• Thromboembolism prophylaxis with LMWH in non-anticoagulated patients without contraindications (Class I, Level B) 1
• Opiates may be considered cautiously for severe dyspnea/anxiety, but associated with nausea and respiratory depression (Class IIb, Level B) 1
• Beta-blockers should be continued cautiously unless hypotensive 1

Critical Medications to AVOID

• Diltiazem or verapamil - increase HF worsening and hospitalization risk (Class III, Level C) 1
• Triple combination of ACE-I + ARB + MRA - increases renal dysfunction and hyperkalemia (Class III, Level C) 1

Discharge Criteria and Follow-up

Patients should NOT be discharged with residual congestion, as this predicts poor outcomes and early rehospitalization 4, 2. Ensure adequate decongestion before discharge and arrange early follow-up within 2 weeks to optimize guideline-directed medical therapy 2.

The evidence strongly emphasizes that decongestion is the primary therapeutic target in AHF, as persistent congestion drives organ dysfunction, symptoms, and adverse outcomes 4. The treatment approach must be aggressive yet carefully monitored, with diuretics as the foundation and other therapies added based on hemodynamic profile and response.